Becerra Testimony Hints At Hard Line on Drug Prices, Medicare Advantage Payments

As policymakers consider proposals to revamp Medicare Part D, HHS secretary nominee and California Attorney General Xavier Becerra (D) during his Senate confirmation hearings last week vowed to make reducing the cost of prescription drugs a priority — although details on such a plan were scant. Meanwhile, his comments around ensuring a “level playing field” between Original Medicare and Medicare Advantage could have implications for MA plan reimbursement.

During a Feb. 23 Senate Health Committee hearing, Bernie Sanders (I-Vt.) was one of several senators who queried Becerra about drug pricing and asked him for “more specificity as to how we take on the drug companies and lower drug costs.” Becerra’s response, which did not appear to satisfy a skeptical Sanders, was that he would “deal with it swiftly” and that the government must take on drugmakers “by trying to go behind the curtain” to determine how they reach their prices.

© 2022 MMIT
Lauren Flynn Kelly

Lauren Flynn Kelly Managing Editor, Radar on Medicare Advantage

Lauren has been covering health business issues, including drug benefits and specialty pharmacy, for more than a decade. She served as editor of Drug Benefit News (the predecessor to Radar on Drug Benefits) from 2004 to 2005 and again from 2011 to 2016, and now manages Radar on Medicare Advantage. Lauren graduated from Vassar College with a B.A. in English.

Related Posts

magnifying-glass-and-report
October 6

Medicaid Plans Aren’t Properly Reporting MLR Data, OIG Finds

READ MORE
call-center
October 6

New Third-Party Marketing Oversight Duties Have Industry Scrambling Before AEP

READ MORE
gavel-and-lawsuit
October 6

Delaware Is Latest State to Face Retiree Pushback on MA Transition

READ MORE

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today